The latest price target for Ocular Therapeutix (NASDAQ:OCUL) was reported by Chardan Capital on December 9, 2025. The analyst firm set a price target for $21.00 expecting OCUL to rise to within 12 months (a possible 51.95% upside). 23 analyst firms have reported ratings in the last year.

The latest analyst rating for Ocular Therapeutix (NASDAQ:OCUL) was provided by Chardan Capital, and Ocular Therapeutix maintained their buy rating.

The last upgrade for Ocular Therapeutix Inc happened on June 20, 2024 when TD Cowen raised their price target to $11. TD Cowen previously had a hold for Ocular Therapeutix Inc.

There is no last downgrade for Ocular Therapeutix.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ocular Therapeutix, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ocular Therapeutix was filed on December 9, 2025 so you should expect the next rating to be made available sometime around December 9, 2026.

While ratings are subjective and will change, the latest Ocular Therapeutix (OCUL) rating was a maintained with a price target of $21.00 to $21.00. The current price Ocular Therapeutix (OCUL) is trading at is $13.82, which is out of the analyst’s predicted range.